Gender Differences in Alzheimer’s Screening and Risk Factors

Research indicates that the risk of developing Alzheimer’s disease and the effectiveness of risk assessment tools vary significantly based on sex and gender. These differences impact the overall lifetime risk of the disease and highlight a need for more inclusive, gender-sensitive screening and research methodologies.

According to a report published in May 2023 by Neelum T. Aggarwal of the Rush Alzheimer’s Disease Center and Michelle M. Mielke of the Wake Forest University School of Medicine, the lifetime risk of acquiring Alzheimer’s disease for individuals aged 65 is 21.2% for females and 11.6% for males.

The Role of Age and Life Expectancy

Age remains the most significant risk factor for Alzheimer’s disease dementia. In a 2018 analysis published in Psychiatr Times, Michelle M. Mielke of the Mayo Clinic noted that women generally have a longer life expectancy than men, which contributes to the higher prevalence of the disease among women.

Alzheimer’s disease is the most common form of dementia, accounting for 60% to 70% of all cases. It is characterized as a progressive neurodegenerative disease that results in behavioral changes, cognitive deficits, and memory loss.

The biological hallmarks of the disease include neurodegeneration, the presence of intracellular neurofibrillary tangles, and extracellular amyloid-beta plaques.

Expanding Research to Gender Identity

While traditional research has focused on biological sex, newer studies are evaluating how gender identity influences dementia risk. A study published on July 26, 2023, in Alzheimers Dement, evaluated risk factors and risk scores among cisgender, transgender, and non-binary adults.

The research, conducted by Brooke Brady and colleagues from the University of New South Wales Sydney, Neuroscience Research Australia, and the UNSW Ageing Futures Institute, explored how different gender identity groups endorse various protective and risk factors for Alzheimer’s disease and dementia.

This research aims to identify significant between-group differences in how risk and protective factors are reported, suggesting that a one-size-fits-all approach to risk scoring may not be accurate for all populations.

Challenges in Diagnosis and Screening

The disparity in risk between men and women suggests that screening tools may function differently across these groups. Barriers to effective care often include the underestimation of morbidity associated with the disease by the public and healthcare professionals, as well as failures to diagnose dementia early in the course of the disease.

The inconsistent use of appropriate medications for treatment further complicates the patient journey, which varies based on sex and gender.

Current scientific efforts are focused on identifying more precise biomarkers and risk factors to improve early detection. This includes examining the specific ways in which the patient journey differs for women, who represent the majority of dementia cases.

Public Health Implications

The burden of Alzheimer’s disease is increasing as the global population ages. In the United States, more than five million people have a diagnosis, and estimates from 2018 suggested that 14 to 16 million people could be diagnosed by 2050 if new interventions to delay or prevent the onset are not identified.

To address these trends, researchers emphasize the necessity of gender-sensitive research to ensure that screening tools and treatments are effective for all patients regardless of sex or gender identity.

• Lifetime risk at age 65: 21.2% for females and 11.6% for males.
• Primary risk factor: Age, coupled with longer female life expectancy.
• Disease prevalence: Alzheimer’s accounts for 60% to 70% of all dementia cases.
• Research scope: Now expanding to include transgender and non-binary adults to refine risk scores.